• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Epidermolysis Bullosa - Pipeline Review, H2 2011 - Product Image

Epidermolysis Bullosa - Pipeline Review, H2 2011

  • Published: August 2011
  • 34 pages
  • Global Markets Direct

Epidermolysis Bullosa - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Epidermolysis Bullosa - Pipeline Review, H2 2011', provides an overview of the Epidermolysis Bullosa therapeutic pipeline. This report provides information on the therapeutic development for Epidermolysis Bullosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa. 'Epidermolysis Bullosa - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Epidermolysis Bullosa.
- A review of the Epidermolysis Bullosa products under development by companies and READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Epidermolysis Bullosa Overview
Therapeutics Development
An Overview of Pipeline Products for Epidermolysis Bullosa
Epidermolysis Bullosa Therapeutics under Development by Companies
Epidermolysis Bullosa Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Epidermolysis Bullosa Therapeutics - Products under Development by Companies
Epidermolysis Bullosa Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Epidermolysis Bullosa Therapeutics Development
RegeneRx Biopharmaceuticals, Inc.
Cellerix, S.A.
Birken GmbH
Epidermolysis Bullosa - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RGN-137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TB4 peptide research programme - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cx501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dysport - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polyphenon E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alwextin cream - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oleogel-S-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epidermolysis Bullosa Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Epidermolysis Bullosa, H2 2011
Products under Development for Epidermolysis Bullosa – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
RegeneRx Biopharmaceuticals, Inc., 2011
Cellerix, S.A., 2011
Birken GmbH, 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Epidermolysis Bullosa Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Epidermolysis Bullosa, H2 2011
Products under Development for Epidermolysis Bullosa – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos